[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Cancer J Clin, 2021, 71, 209-249. [2] Jayson GC, Kohn EC, Kitchener, et al. Ovarian cancer[J]. Lancet, 2014, 384, 1376-1388. [3] Hinchcliff E, Westin SN, Herzog TJ. State of the science: contemporary front-line treatment of advanced ovarian cancer[J]. Gynecol Oncol, 2022, 166, 18-24. [4] Bartoletti M, Musacchio L, Giannone G, et al. Emerging molecular alterations leading to histology-specifictargeted therapies in ovarian cancer beyond PARP inhibitors[J]. Cancer Treat Rev, 2021, 101:102298. doi: 10.1016/j.ctrv.2021.102298. [5] Gogineni V, Morand S, Staats H, et al. Current ovarian cancer maintenance strategies and promising new developments[J]. Cancer, 2021, 12:38-53. [6] González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med, 2019, 381:2391-2402. [7] Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer[J]. N Engl J Med, 2019, 381:2416-2428. [8] Li M, Ma D, Chang Z. Current understanding of CREPT and p15RS, carboxy-terminal domain (CTD)-interacting proteins, in human cancers[J]. Oncogene, 2021, 40:705-716. [9] Li W, Zheng G, Xia J, et al. Cell cycle related and expression-elevated protein in tumor overexpression is associated with proliferation behaviors and poor prognosis in nonsmall-cell lung cancer[J]. Cancer Sci, 2018, 109:1012-1023. [10] Jiang J, Yang X, He X, et al. MicroRNA449b-5p suppresses the growth and invasion of breast cancer cells via inhibiting CREPT-mediated Wnt/beta-catenin signaling[J]. Chem Biol Interact, 2019, 302:74-82 [11] Sun M, Si G, Sun HS, et al. Inhibition of CREPT restrains gastric cancer growth by regulation of cycle arrest, migration and apoptosis via ROS-regulated p53 pathway[J]. Biochem Biophys Res Commun, 2018, 496:1183-1190. [12] Lu D, Wu Y, Wang Y, et al. CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes[J]. Cancer Cell, 2012, 21: 92-104. [13] Zhai W, Ye X, Wang Y, et al. CREPT/RPRD1B promotes tumorigenesis through STAT3-driven gene transcription in a p300-dependent manner[J]. Br J Cancer, 2021, 124: 1437-1448. [14] Manfioletti G, Fedele M. Epithelial-mesenchymal transition (EMT)[J]. Int J Mol Sci, 2023, 24:11386. doi: 10.3390/ijms241411386. |